Browse CLDND2

Summary
SymbolCLDND2
Nameclaudin domain containing 2
Aliases MGC33839; Claudin domain-containing protein 2
Chromosomal Location19q13.41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Multi-pass membrane protein
Domain PF00822 PMP-22/EMP/MP20/Claudin family
Function

-

> Gene Ontology
 
Biological Process -
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolCLDND2
Nameclaudin domain containing 2
Aliases MGC33839; Claudin domain-containing protein 2
Chromosomal Location19q13.41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CLDND2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCLDND2
Nameclaudin domain containing 2
Aliases MGC33839; Claudin domain-containing protein 2
Chromosomal Location19q13.41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CLDND2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCLDND2
Nameclaudin domain containing 2
Aliases MGC33839; Claudin domain-containing protein 2
Chromosomal Location19q13.41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CLDND2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1880.286
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0420.904
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2890.374
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4940.397
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8350.376
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0760.945
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.9810.0319
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.9730.239
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.1260.163
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6920.439
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.4620.681
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1890.303
> Mutation difference between responders and non-responders
 

There is no record.

Summary
SymbolCLDND2
Nameclaudin domain containing 2
Aliases MGC33839; Claudin domain-containing protein 2
Chromosomal Location19q13.41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CLDND2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCLDND2
Nameclaudin domain containing 2
Aliases MGC33839; Claudin domain-containing protein 2
Chromosomal Location19q13.41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CLDND2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CLDND2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCLDND2
Nameclaudin domain containing 2
Aliases MGC33839; Claudin domain-containing protein 2
Chromosomal Location19q13.41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CLDND2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCLDND2
Nameclaudin domain containing 2
Aliases MGC33839; Claudin domain-containing protein 2
Chromosomal Location19q13.41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CLDND2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCLDND2
Nameclaudin domain containing 2
Aliases MGC33839; Claudin domain-containing protein 2
Chromosomal Location19q13.41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CLDND2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCLDND2
Nameclaudin domain containing 2
Aliases MGC33839; Claudin domain-containing protein 2
Chromosomal Location19q13.41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CLDND2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.